Smartkarma AI Primers, Smartkarma

αSK Primers

Smartkarma AI Primers

Smartkarma

Smartkarma unites the fragmented investment industry, connecting institutional investors, independent research providers, and corporates within a single network.

Research Reinvented

Equity Bottom-Up

<ul>
 <li>Coherus is undergoing a significant strategic transformation, divesting its biosimilar portfolio to become a pure-play, revenue-generating oncology company focused on innovative immuno-oncology (I-O) therapies.</li>
 <li>The company's future is now centered on its sole commercial product, LOQTORZI® (toripalimab-tpzi), a next-generation PD-1 inhibitor, and its mid-stage I-O pipeline candidates, casdozokitug and tagmokitug.</li>
 <li>Recent divestitures of its biosimilar assets, including UDENYCA®, have significantly strengthened the balance sheet, providing capital to pay down debt and fund the focused oncology strategy through key clinical milestones in 2026.</li>
</ul>This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.


  Coherus is undergoing a significant strategic transformation, divesting its biosimilar portfolio to become a pure-play, revenue-generating oncology company focused on innovative immuno-oncology (I-O) therapies.
  The company's future is now centered on its sole commercial product, LOQTORZI® (toripalimab-tpzi), a next-generation PD-1 inhibitor, and its mid-stage I-O pipeline candidates, casdozokitug and tagmokitug.
  Recent divestitures of its biosimilar assets, including UDENYCA®, have significantly strengthened the balance sheet, providing capital to pay down debt and fund the focused oncology strategy through key clinical milestones in 2026.
This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

Primer: Coherus Biosciences (CHRS US) - Jul 2026

Global Healthcare Analyst

Tina Banerjee

<ul>
<li>
<a href="https://www.smartkarma.com/entities/shanghai-junshi-biosciences-co-ltd-class-h" target="_blank" data-smartkarma-citation="entities:27760:1" rel="noopener">Junshi Biosciences (1877 HK)</a> reported stellar performance for 1H26, with the company reporting its maiden net profit. Steady revenue growth of toripalimab led to breakthroughs in revenue and profit.</li>
<li>Tuoyi is reporting increasing revenue in China, driven by continued expansion of indications and NRDL coverage. 2Q26 represents 11th consecutive quarter of sequential revenue increase for Tuoyi.</li>
<li>Continued clinical advancement of core pipelines, including bispecific antibody candidate, JS207 and ADC candidate, JS212 with strong clinical trial data for various types of solid tumors enhance visibility beyond toripalimab.  </li>
</ul>



Junshi Biosciences (1877 HK) reported stellar performance for 1H26, with the company reporting its maiden net profit. Steady revenue growth of toripalimab led to breakthroughs in revenue and profit.
Tuoyi is reporting increasing revenue in China, driven by continued expansion of indications and NRDL coverage. 2Q26 represents 11th consecutive quarter of sequential revenue increase for Tuoyi.
Continued clinical advancement of core pipelines, including bispecific antibody candidate, JS207 and ADC candidate, JS212 with strong clinical trial data for various types of solid tumors enhance visibility beyond toripalimab.  


Shanghai Junshi Bioscience (1877 HK): Turns Profitable in 1H26 on Steady Domestic Revenue of Tuoyi

Equity Long-Short Analyst

Pyari Menon

Thematic (Sector/Industry)

<ul>
<li>We compare how a portfolio composed of our top five picks in each of our thematic reports based on datamining technical publications would have performed versus Indices</li>
<li>The size of outperformance for various periods suggests that incorporating innovation quality index that we use to rank companies can be a solid tool to generate alpha.   </li>
<li>We understand that much of the outperformance is generated by positive skew but even backing out the largest two contributors we see solid outperformance.</li>
</ul>


We compare how a portfolio composed of our top five picks in each of our thematic reports based on datamining technical publications would have performed versus Indices
The size of outperformance for various periods suggests that incorporating innovation quality index that we use to rank companies can be a solid tool to generate alpha.   
We understand that much of the outperformance is generated by positive skew but even backing out the largest two contributors we see solid outperformance.


A Look at How a Portfolio Composed of Our Top Five Innovators in Each Report Would Have Performed

HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

<ul>
<li>As this year's policy risks gradually removed, after entering Q4, the healthcare sector has entered the range of investment.</li>
<li>Recently, the National Development and Reform Commission issued the “Notice on the implementation plan of promoting high-quality development of API industry”, indicating related opportunities.</li>
<li>The Beijing Stock Exchange (BSE) officially opened last week. In the field of healthcare, there are ten related companies would be listed in BSE.</li>
</ul>


As this year's policy risks gradually removed, after entering Q4, the healthcare sector has entered the range of investment.
Recently, the National Development and Reform Commission issued the “Notice on the implementation plan of promoting high-quality development of API industry”, indicating related opportunities.
The Beijing Stock Exchange (BSE) officially opened last week. In the field of healthcare, there are ten related companies would be listed in BSE.


China Healthcare Weekly (Nov.19) - Q4 Healthcare Rebound, New Policy on API, Beijing Stock Exchange

In technical publications like patents and research papers, cross-references are made to existing patents and research papers. We believe these mentions and citations can provide valuable insights into the views and impressions of experts in the specific innovations and technologies within a sector and hence the likelihood of success. In this report (which is the first one we are publishing) we have crawled through more than ten years of publications (several thousand) to analyze a subset in the Lifesciences space namely PEPTIDES.  Needless to say the same can be done with respect to other technological areas in other sectors as well.We backtested our methodology (dating three years back) to look for any specific actionable idea the analysis might throw up. We noted that among the small or mid-cap stocks that screened well half were acquired over the next three years Specific to this report we highlight over ten companies that are likely acquisition targets over the next three years. Within those, two companies that screen very well based purely on data mined from the publications and our parameters of number of innovations, number of citations, Recency, and Impact are a Germany based Nasdaq listed - Immatics (IMTX) and US-based Coherus (CHRS)

In technical publications like patents and research papers, cross-references are made to existing patents and research papers. We believe these mentions and citations can provide valuable insights into the views and impressions of experts in the specific innovations and technologies within a sector and hence the likelihood of success. In this report (which is the first one we are publishing) we have crawled through more than ten years of publications (several thousand) to analyze a subset in the Lifesciences space namely PEPTIDES.  Needless to say the same can be done with respect to other technological areas in other sectors as well.We backtested our methodology (dating three years back) to look for any specific actionable idea the analysis might throw up. We noted that among the small or mid-cap stocks that screened well half were acquired over the next three years Specific to this report we highlight over ten companies that are likely acquisition targets over the next three years. Within those, two companies that screen very well based purely on data mined from the publications and our parameters of number of innovations, number of citations, Recency, and Impact are a Germany based Nasdaq listed - Immatics (IMTX) and US-based Coherus (CHRS)

Stock Ideas Based on Data Mined from Technical Publications - A Look Into Peptides

United States

Coherus Biosciences Inc., is a biopharmaceutical company. The Company develops biosimilar therapeutics to aid patients.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Coherus Biosciences (CHRS US)

Primer: Coherus Biosciences (CHRS US) - Jul 2026

Coherus is undergoing a significant strategic transformation, divesting its biosimilar portfolio to become a pure-play, revenue-generating...

αSK Primers

Shanghai Junshi Bioscience (1877 HK): Turns Profitable in 1H26 on Steady Domestic Revenue of Tuoyi

Junshi Bioscience reports maiden net profit in 1H26. Steady sales growth of toripalimab led to breakthroughs in revenue and profit. Continued...

Tina Banerjee

A Look at How a Portfolio Composed of Our Top Five Innovators in Each Report Would Have Performed

Our datamining reports ranks companies within thematic based on innovation quality. We see strong outperformance in a portfolio built using the top...

Pyari Menon

China Healthcare Weekly (Nov.19) - Q4 Healthcare Rebound, New Policy on API, Beijing Stock Exchange

The article analyzed the investment logic and opportunities in healthcare in Q4, the new policy of API industry and potential trend, as well as the...

Xinyao (Criss) Wang

Stock Ideas Based on Data Mined from Technical Publications - A Look Into Peptides

We have screened for stock ideas in the area of PEPTIDES by datamining citations by industry experts in thousands of technical publications over...

Pyari Menon

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)